As part of the MAINSTREAM project, Favalli and colleagues conducted a seroprevalence cross-sectional study between 4th May and 16th June 2020 to estimate the prevalence of anti-SARS-CoV-2 antibodies in a large cohort of people with rheumatoid arthritis (RA) or spondyloarthritis (SpA) treated with biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) in a COVID-19 high-endemic area (Lombardy, Italy).Over this time, 300 people were tested for IgG, IgM and IgA antibodies against three viral antigens–nucleoprotein, spike protein, and the receptor-binding domain. These data were compared with those observed in the healthy population in the same period and region. Everyone taking part also completed a questionnaire to collect information about symptoms consistent with COVID-19, risk factors, and comorbidities.

Overall, 65% of people taking part had RA, 23% had psoriatic arthritis, and 21% had ankylosing spondylitis. Most people were being treated with tumour necrosis factor inhibitors (TNFi;57%),and the remainder were receiving abatacept (20%),interleukin-6 inhibitors (IL-6i;11%), or janus kinase inhibitors (JAKi;5%).Of the 300 people, 4 had a prior diagnosis of COVID-19 defined by nasopharyngeal swab.

Immunoglobulin titres were evaluated resulting in 9%, 13.6%, and 13.3% positive patients for IgG, IgM and IgA, respectively, and there was no significant difference to the healthy population. Among seropositive patients, 55.3% were asymptomatic, 16% had minor and 19.6% major symptoms, 7.1% were hospitalized. No deaths or admission to intensive care occurred. IgM, IgG and IgA titres to the receptor binding domain of the virus were higher in patients with both minor and major symptoms compared with asymptomatic ones. No differences were found between seronegative and seropositive patients in relation to age, sex, rheumatic diagnosis, and treatment with cs- and b/tsDMARDs or corticosteroids. A relative increased risk was associated with obesity and presence of at least two comorbidities.

This study confirms that, even in a cohort of rheumatic patients, the spread of SARS-CoV-2 infection is much greater than that observed by capturing only swab-diagnosed COVID-19 cases. The underlying rheumatic disease and ongoing therapy with b/tsDMARD does not seem to impact SARS-CoV-2 antibody positivity, which conversely seems to be associated to symptomaticCOVID-19 and presence of comorbidities.

Source: European Alliance of Associations for Rheumatology, EULAR
Full bibliographic information

Favalli EG, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in rheumatic patients treated with biological and targeted therapy living in Lombardy, Italy (MAINSTREAM project). Presented at EULAR 2021; poster POS0048